ARS Pharmaceuticals
SPRY
113 hedge funds and large institutions have $612M invested in ARS Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 36 increasing their positions, 27 reducing their positions, and 14 closing their positions.
528% more call options, than puts
Call options by funds: $6.42M | Put options by funds: $1.02M
93% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 14
70% more capital invested
Capital invested by funds: $359M → $612M (+$253M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
33% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 27
13% more funds holding
Funds holding: 100 → 113 (+13)
6.2% less ownership
Funds ownership: 68.26% → 62.06% (-6.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$10.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$7.66M |
| 3 |
PA
Perceptive Advisors
New York
|
+$6.47M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.82M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$2.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CST
Charles Schwab Trust
Henderson,
Nevada
|
-$21.9M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$11M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$8.75M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$8.56M |
| 5 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$6.23M |
SPRY Hedge Fund Activity: Q1 2024 in Review
113 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q1 2024, worth a combined $612M — up 70% from $359M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new SPRY positions and 14 closed out — a net gain of 13 holders — while 36 added to existing stakes and 27 trimmed.
The largest buyer was RA Capital Management, adding an estimated $10.4M. The largest seller was Charles Schwab Trust, exiting entirely with an estimated $21.9M sold.
- 113 institutional investors held ARS Pharmaceuticals (SPRY) as of Q1 2024, up from 100 in Q4 2023.
- Funds reported $612M of ARS Pharmaceuticals stock for Q1 2024, up 70% quarter-over-quarter.
- 27 funds opened new ARS Pharmaceuticals positions in Q1 2024 and 14 closed out, a net change of +13 holders.
- The largest ARS Pharmaceuticals buyer in Q1 2024 was RA Capital Management, an estimated $10.4M added.
- The largest ARS Pharmaceuticals seller in Q1 2024 was Charles Schwab Trust, an estimated $21.9M sold.
Based on aggregated 13F filings for Q1 2024.